Skip to main content
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · AUPH ISIN · CA05156V1022 LEI · 5299008YP2BW4570ML28 US Manufacturing
Open in API
Filings indexed 582 across all filing types
Latest filing 2014-11-12 Interim / Quarterly Rep…
Country CA Canada
Listing US AUPH

About Aurinia Pharmaceuticals Inc.

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering therapies for patients with severe autoimmune diseases that have high unmet medical needs. The company's principal product is LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus. Aurinia's research and development efforts are centered on immunomodulating therapies for various autoimmune and kidney-related diseases.

Recent filings

Filing Released Lang Actions
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Aurinia Pharmaceuticals Inc., dated November 12, 2014. It includes an exhibit index listing a news release of third quarter financial results, interim financial statements, MD&A, and certifications of interim filings by CEO and CFO. The presence of interim financial statements and MD&A indicates substantive financial data for a period shorter than a full fiscal year. Form 6-K is typically used for interim or quarterly reports by foreign private issuers. The document length is 2283 characters, which is relatively short but includes actual financial statements and management discussion. Therefore, the document is best classified as an Interim / Quarterly Report (IR).
2014-11-12 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It includes a signature page and an exhibit index referencing a news release about an upcoming meeting and webcast. The document length is short (2007 characters) and does not contain detailed financial statements or substantive financial data. It primarily serves as a regulatory filing to inform the SEC and investors about corporate events and disclosures. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2014-10-21 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Aurinia Pharmaceuticals Inc., with the SEC. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. The document includes a signature page and an exhibit index referencing a news release about the company beginning trading on NASDAQ. The document length is short (1964 characters), and it primarily serves as a regulatory filing to report this information to the SEC. There is no substantive financial data, detailed financial statements, or management discussion present. Therefore, this document is best classified as a Regulatory Filing (RNS) rather than a full report or announcement of a report publication.
2014-09-02 English
AUTO-GENERATED PAPER DOCUMENT
Regulatory Filings
2014-08-29 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Aurinia Pharmaceuticals Inc., dated August 14, 2014. The exhibit index lists several exhibits including a news release of second quarter financial results, interim financial statements, MD&A, and certifications of interim filings by CEO and CFO. The presence of interim financial statements and MD&A indicates this filing contains substantive financial data for a period shorter than a full fiscal year. The document length is 2217 characters, which is relatively short but includes actual financial data and management discussion. Therefore, this is an Interim / Quarterly Report (IR).
2014-08-15 English
FORM 6-K
Board/Management Information Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It is dated July 29, 2014, and includes a signature from the CFO. The content includes an exhibit index referencing an addition to the board of directors. The document length is 1902 characters, which is relatively short and does not contain detailed financial statements or comprehensive management discussion. The primary content is an announcement about a board change (addition of financial expertise to the board). Therefore, this document fits best under Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2014-07-29 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.